
AMS Grows, Five Sites to Close
Source announcement: 16 September 2026
Advanced Medical Solutions (AMS) reported £115.5 million in first-half 2026 revenue, up 4%. Surgical revenue reached £91.4 million, also up 4%.
The Suture, Clips and VTO category grew 9% to £42.5 million, or 7% at constant currency. This combined category is broader than sutures alone.
Internal Fixation and Sealants revenue increased 36% to £4.9 million, driven by US LIQUIFIX sales. Global LiquiBand revenue fell 8%, against a prior period boosted by partner order timing.
AMS is also consolidating suture and collagen operations. Five sites in Germany and Czechia are expected to stop manufacturing by the end of March 2027.
Adjusted EBITDA rose 8% to £26.3 million. Reported pre-tax profit fell to £0.3 million, reflecting £12.4 million in exceptional costs linked to restructuring and the proposed acquisition.
At the announcement date, AMS expected the H.B. Fuller acquisition to complete in Q4 2026, subject to remaining conditions.
MatrixLabs perspective: growth alongside manufacturing consolidation highlights the importance of supply continuity and partner execution. This is our interpretation, not an AMS forecast.
.jpeg)



Comments